Quince Therapeutics Q2 2026: Net loss $75.5M, cash $116M, Orphai acquisition closed

Quince Therapeutics, Inc.

Completed stock-for-stock Orphai acquisition adding LAM-001 inhaled rapamycin; concurrent $115M private placement, net $103.6M.
Cash and equivalents $116M as of June 30, 2026, expected to fund operations through end of 2028.
Net loss $75.5M ($12.31/share) vs $16.0M ($68.75/share) in Q2 2025; G&A up to $16.6M on one-time stock comp.
Phase 2b PH-ILD data expected Q1 2028; BOS Phase 2 data Q1 2027; SAPH trial start late 2026.
Phase 2a ATS data: 6MWD +67.4m, PVR -33.9% in PH-ILD patients; drug generally well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.